- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A systematic review of moral reasons on orphan drug reimbursement ; volume:16 ; number:1 ; day:30 ; month:6 ; year:2021 ; pages:1-21 ; date:12.2021
Orphanet journal of rare diseases ; 16, Heft 1 (30.6.2021), 1-21, 12.2021
- Creator
-
Zimmermann, Bettina M.
Eichinger, Johanna
Baumgartner, Matthias R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-021-01925-y
- URN
-
urn:nbn:de:101:1-2021101221530994331798
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zimmermann, Bettina M.
- Eichinger, Johanna
- Baumgartner, Matthias R.
- SpringerLink (Online service)
Other Objects (12)
Reimbursement of orphan drugs in Belgium: what (else) matters?
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
Markenführung Orphan Drugs
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Predictors of orphan drug approval
Evidenz zu Orphan Drugs : Arbeitspapier
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Reimbursement of orphan drugs in Belgium: what (else) matters?
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
Markenführung Orphan Drugs
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Predictors of orphan drug approval
Evidenz zu Orphan Drugs : Arbeitspapier
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Reimbursement of orphan drugs in Belgium: what (else) matters?
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
Markenführung Orphan Drugs
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Predictors of orphan drug approval
Evidenz zu Orphan Drugs : Arbeitspapier